Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% – Time to Sell?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)’s stock price traded down 12.8% on Wednesday . The stock traded as low as $261.27 and last traded at $261.27. 105 shares traded hands during trading, a decline of 67% from the average session volume of 317 shares. The stock had previously closed at $299.45.

Bio-Rad Laboratories Trading Up 1.1%

The stock’s 50 day moving average is $276.49 and its 200-day moving average is $295.24. The company has a market cap of $7.05 billion, a P/E ratio of 43.04 and a beta of 0.96. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO.B) last released its quarterly earnings data on Thursday, April 30th. The company reported $1.89 earnings per share for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.